List With HCPCS Codes For Other Drugs and Service Fees

The HCPCS codes for Other Drugs and Service Fees (Q2041-Q3031) cover a range of drugs, services, and fees related to various medical procedures and treatments. These codes include therapies such as Axicabtagene ciloleucel, Tisagenlecleucel, Sipuleucel-T, and Brexucabtagene autoleucel, as well as drugs like doxorubicin hydrochloride liposomal. They also encompass services and supplies used in the home for the administration of intravenous immune globulin (ivig), radioelements for brachytherapy, telehealth originating site facility fees, and collagen skin tests.

1. HCPCS Code Q2041

HCPCS Q2041 describes the therapy Axicabtagene ciloleucel, which involves the infusion of up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.

2. HCPCS Code Q2042

HCPCS Q2042 represents the therapy Tisagenlecleucel, which involves the infusion of up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.

3. HCPCS Code Q2043

HCPCS Q2043 represents the therapy Sipuleucel-T, which involves the infusion of a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion.

4. HCPCS Code Q2049

HCPCS Q2049 represents the drug doxorubicin hydrochloride liposomal (imported Lipodox), which is administered through injection and contains 10 mg of the medication.

5. HCPCS Code Q2050

HCPCS Q2050 represents the drug doxorubicin hydrochloride liposomal (not otherwise specified), which is administered through injection and contains 10 mg of the medication.

6. HCPCS Code Q2052

HCPCS Q2052 covers the services, supplies, and accessories used in the home for the administration of intravenous immune globulin (ivig).

7. HCPCS Code Q2053

HCPCS Q2053 describes the therapy Brexucabtagene autoleucel, which involves the infusion of up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.

8. HCPCS Code Q2054

HCPCS Q2054 represents the therapy Lisocabtagene maraleucel, which involves the infusion of up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.

9. HCPCS Code Q2055

HCPCS Q2055 represents the therapy Idecabtagene vicleucel, which involves the infusion of up to 460 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.

10. HCPCS Code Q2056

HCPCS Q2056 represents the therapy Ciltacabtagene autoleucel, which involves the infusion of up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.

11. HCPCS Code Q3001

HCPCS Q3001 covers the radioelements used for brachytherapy, regardless of the specific type, with each code representing a single radioelement.

12. HCPCS Code Q3014

HCPCS Q3014 represents the telehealth originating site facility fee, which is charged for the use of telehealth services at the originating site.

13. HCPCS Code Q3027

HCPCS Q3027 represents the injection of interferon beta-1a, 1 mcg, for intramuscular use.

14. HCPCS Code Q3028

HCPCS Q3028 represents the injection of interferon beta-1a, 1 mcg, for subcutaneous use.

15. HCPCS Code Q3031

HCPCS Q3031 represents the collagen skin test, which is used to determine an individual’s sensitivity or allergic reaction to collagen.